The design, synthesis, and evaluation of organ-specific iron chelators

Journal of Medicinal Chemistry

Volumn 49, Issue 24, 2006, Pages 7032-7043

  Bergeron, Raymond J ^a   Wiegand, Jan ^a   McManis, James S ^a   Bharti, Neelam ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,5 DIHYDROXYPHENYL) 4,5 DIHYDRO 4 METHYL 4 THIAZOLECARBOXYLIC ACID; 2 (2,5 DIHYDROXYPHENYL) 4,5 DIHYDRO 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 (2 HYDROXY 4 METHOXYPHENYL) 4 METHYL 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 (2 HYDROXY 5 METHOXYPHENYL) 4 METHYL 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 (2 HYDROXY 5 METHOXYPHENYL) 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 (3,4 DIMETHOXY 2 HYDROXYPHENYL) 4 METHYL 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 (3,4 DIMETHOXY 2 HYDROXYPHENYL) 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 [2 HYDROXY 4 (3,6,9 TRIOXADECYLOXY)PHENYL] 4 METHYL 4 THIAZOLECARBOXYLIC ACID; DEFERASIROX; DEFERIPRONE; DEFERITRIN; DEFERRIFERRITHIOCIN; IRON CHELATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; IRON CHELATION; IRON OVERLOAD; LIPOPHILICITY; MALE; NONHUMAN; PRIMATE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BILE; CARBOXYLIC ACIDS; CEBUS; DIHYDROPYRIDINES; IRON CHELATING AGENTS; IRON-DEXTRAN COMPLEX; KIDNEY; LIVER; MALE; MYOCARDIUM; ORGAN SPECIFICITY; PANCREAS; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TISSUE DISTRIBUTION;

EID: 33845351575     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0608816     Document Type: Article

References (52)

1. Raymond, K. N.; Carrano, C. J. Coordination Chemistry and Microbial Iron Transport. Acc. Chem. Res. 1979, 12, 183-190.
2. Byers, B. R.; Arceneaux, J. E. Microbial Iron Transport: Iron Acquisition by Pathogenic Microorganisms. Met. Ions Biol. Syst. 1998, 35, 37-66.
3. Bergeron, R. J. Iron: A Controlling Nutrient in Proliferative Processes. Trends Biochem. Sci. 1986, 11, 133-136.
4. Theil, E. C.; Huynh, B. H. Ferritin Mineralization: Ferroxidation and Beyond. J. Inorg. Biochem. 1997, 67, 30.
5. Kalinowski, D. S.; Richardson, D. R. The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer. Pharmacol. Rev. 2005, 57, 547-583.
6. Brittenham, G. M. Disorders of Iron Metabolism: Iron Deficiency and Overload. In Hematology: Basic Principles and Practice, 3rd ed.; Hoffman, R., Benz, E. J., Shattil, S. J., Furie, B., Cohen, H. J., et al., Eds.; Churchill Livingstone: New York, 2000; pp 397-428.
7. Graf, E.; Mahoney, J. R.; Bryant, R. G.; Eaton, J. W. Iron-Catalyzed Hydroxyl Radical Formation. Stringent Requirement for Free Iron Coordination Site. J. Biol. Chem. 1984, 259, 3620-3624.
8. Halliwell, B. Free Radicals and Antioxidants: A Personal View. Nutr. Rev. 1994, 52, 253-265.
9. Halliwell, B. Iron, Oxidative Damage, and Chelating Agents. In The Development of Iron Chelators for Clinical Use; Bergeron, R. J., Brittenham, G. M., Eds.; CRC: Boca Raton, 1994; pp 33-56.
10. Koppenol, W. Kinetics and Mechanism of the Fenton Reaction: Implications for Iron Toxicity. In Iron Chelators: New Development Strategies; Badman, D. G., Bergeron, R. J., Brittenham, G. M., Eds.; Saratoga: Ponte Vedra Beach, FL, 2000; pp. 3-10.
11. Babbs, C. F. Oxygen Radicals in Ulcerative Colitis. Free Radical Biol. Med. 1992, 13, 169-181.
12. Hazen, S. L.; d'Avignon, A.; Anderson, M. M.; Hsu, F. F.; Heinecke, J. W. Human Neutrophils Employ the Myeloperoxidase-Hydrogen Peroxide-Chloride System to Oxidize α-Amino Acids to a Family of Reactive Aldehydes. Mechanistic Studies Identifying Labile Intermediates along the Reaction Pathway. J. Biol. Chem. 1998, 273, 4997-5005.
13. Olivieri, N. F.; Brittenham, G. M. Iron-chelating Therapy and the Treatment of Thalassemia. Blood 1997, 89, 739-761.
14. Vichinsky, E. P. Current Issues with Blood Transfusions in Sickle Cell Disease. Semin. Hematol. 2001, 38, 14-22.
15. Kersten, M. J.; Lange, R.; Smeets, M. E.; Vreugdenhil, G.; Roozendaal, K. J.; Lameijer, W.; Goudsmit, R. Long-Term Treatment of Transfusional Iron Overload with the Oral Iron Chelator Deferiprone (L1): A Dutch Multicenter Trial. Ann. Hematol. 1996, 73, 247-252.
16. Conrad, M. E.; Umbreit, J. N.; Moore, E. G. Iron Absorption and Transport. Am. J. Med. Sci. 1999, 318, 213-229.
17. Lieu, P. T.; Heiskala, M.; Peterson, P. A.; Yang, Y. The Roles of Iron in Health and Disease. Mol. Aspects Med. 2001, 22, 1-87.
18. Angelucci, E.; Brittenham, G. M.; McLaren, C. E.; Ripalti, M.; Baronciani, D.; Giardini, C.; Galimberti, M.; Polchi, P.; Lucarelli, G. Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major. N. Engl. J. Med. 2000, 343, 327-331.
19. Bonkovsky, H. L.; Lambrecht, R. W. Iron-Induced Liver Injury. Clin. Liver Dis. 2000, 4, 409-429, vi-vii.
20. Pietrangelo, A. Mechanism of Iron Toxicity. Adv. Exp. Med. Biol. 2002, 509, 19-43.
21. Cario, H.; Holl, R. W.; Debatin, K. M.; Kohne, E. Insulin Sensitivity and β-Cell Secretion in Thalassaemia Major with Secondary Haemochromatosis: Assessment by Oral Glucose Tolerance Test. Eur. J. Pediatr. 2003, 162, 139-146.
22. Wojcik, J. P.; Speechley, M. R.; Kertesz, A. E.; Chakrabarti, S.; Adams, P. C. Natural History of C282Y Homozygotes for Hemochromatosis. Can. J. Gastroenterol. 2002, 16, 297-302.
23. Brittenham, G. M.; Griffith, P. M.; Nienhuis, A. W.; McLaren, C. E.; Young, N. S.; Tucker, E. E.; Allen, C. J.; Farrell, D. E.; Harris, J. W. Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. N. Engl. J. Med. 1994, 331, 567-573.
24. Zurlo, M. G.; De Stefano, P.; Borgna-Pignatti, C.; Di Palma, A.; Piga, A.; Melevendi, C.; Di Gregorio, F.; Burattini, M. G.; Terzoli, S. Survival and Causes of Death in Thalassaemia Major. Lancet 1989, 2, 27-30.
25. Chua, A. C. G.; Olynyk, J. K.; Leedman, P. J.; Trinder, D. Nontransferrin-Bound Iron Uptake by Hepatocytes Is Increased in the Hfe Knockout Mouse Model of Hereditary Hemochromatosis. Blood 2004, 104, 1519-1525.
26. 2+ Channels Provide a Major Pathway for Iron Entry into Cardiomyocytes in Iron-Overload Cardiomyopathy. Nat. Med. 2003, 9, 1187-1194.
27. Brittenham, G. M. Iron Chelators and Iron Toxicity. Alcohol 2003, 30, 151-158.
28. Davis, B. A.; Porter, J. B. Long-Term Outcome of Continuous 24-Hour Deferoxamine Infusion via Indwelling Intravenous Catheters in High-Risk β-Thalassemia. Blood 2000, 95, 1229-1236.
29. Davis, B. A.; Porter, J. B. Results of Long Term Iron Chelation Treatment with Deferoxamine. Adv. Exp. Med. Biol. 2002, 509, 91-125.
30. Naegeli, H.-U.; Zähner, H. Metabolites of Microorganisms. Part 193. Ferrithiocin. Helv. Chim. Acta 1980, 63, 1400-1406.
31. Hahn, F. E.; McMurry, T. J.; Hugi, A.; Raymond, K. N. Coordination Chemistry of Microbial Iron Transport. 42. Structural and Spectroscopic Characterization of Diastereomeric Cr(III) and Co(III) Complexes of Desferriferrithiocin. J. Am. Chem. Soc. 1990, 112, 1854-1860.
32. Anderegg, G.; Räber, M. Metal Complex Formation of a New Siderophore Desferrithiocin and of Three Related Ligands. J. Chem. Soc., Chem. Commun. 1990, 1194-1196.
33. Bergeron, R. J.; Wiegand, J.; Dionis, J. B.; Egli-Karmakka, M.; Frei, J.; Huxley-Tencer, A.; Peter, H. H. Evaluation of Desferrithiocin and Its Synthetic Analogues as Orally Effective Iron Chelators. J. Med. Chem. 1991, 34, 2072-2078.
34. Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Vinson, J. R. T.; Luchetta, G.; Evans, K. M.; Peter, H.; Jenny, H.-B. A Comparative Evaluation of Iron Clearance Models. Ann. N. Y. Acad. Sci. 1990, 612, 378-393.
35. Bergeron, R. J.; Streiff, R. R.; Creary, E. A.; Daniels, R. D., Jr.; King, W.; Luchetta, G.; Wiegand, J.; Moerker, T.; Peter, H. H. A Comparative Study of the Iron-Clearing Properties of Desferrithiocin Analogues with Desferrioxamine B in a Cebus Monkey Model. Blood 1993, 81, 2166-2173.
36. Bergeron, R. J.; Wiegand, J.; Weimar, W. R.; Vinson, J. R. T.; Bussenius, J.; Yao, G. W.; McManis, J. S. Desazadesmethyldesferrithiocin Analogues as Orally Effective Iron Chelators. J. Med. Chem. 1999, 42, 95-108.
37. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; McCosar, B. H.; Weimar, W. R.; Brittenham, G. M.; Smith, R. E. Effects of C-4 Stereochemistry and C-4′ Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues. J. Med. Chem. 1999, 42, 2432-2440.
38. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Bussenius, J.; Smith, R. E.; Weimar, W. R. Methoxylation of Desazadesferrithiocin Analogues: Enhanced Iron Clearing Efficiency. J. Med. Chem. 2003, 46, 1470-1477.
39. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Vinson, J. R. T.; Yao, H.; Bharti, N.; Rocca, J. R. (S)-4,5-Dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl- 4-thiazolecarboxylic Acid Polyethers: A Solution to Nephrotoxicity. J. Med. Chem. 2006, 49, 2772-2783.
40. Shinoda, J. The Constitution of Gentisin. J. Chem. Soc. 1927, 1983-1985.
41. Singh, S. B.; Pettit, G. R. Antineoplastic Agents. 166. Isolation, Structure, and Synthesis of Combretastatin C-1. J. Org. Chem. 1989, 54, 4105-4114.
42. Chantimakorn, V.; Nimgirawath, S. Syntheses of the Benzylisoquinoline Alkaloids Isosevanine and Berbithine. Aust. J. Chem. 1989, 42, 209-213.
43. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Weimar, W. R.; Park, J.-H.; Eiler-McManis, E.; Bergeron, J.; Brittenham, G. M. Partition-Variant Desferrithiocin Analogues: Organ Targeting and Increased Iron Clearance. J. Med. Chem. 2005, 48, 821-831.
44. Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Luchetta, G.; Creary, E. A.; Peter, H. H. A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-hydroxypyrid-4-one, 1,2-Diethyl-3-hydroxypyrid-4-one, and Deferoxamine. Blood 1992, 79, 1882-1890.
45. Wood, J. K.; Milner, P. F.; Pathak, U. N. The Metabolism of Iron-Dextran Given as a Total-Dose Infusion to Iron Deficient Jamaican Subjects. Br. J. Haematol. 1968, 14, 119-129.
46. Bergeron, R. J.; Wiegand, J.; Brittenham, G. M. HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood 1998, 91, 1446-1452.
47. Bergeron, R. J.; Wiegand, J.; Wollenweber, M.; McManis, J. S.; Algee, S. E.; Ratliff-Thompson, K. Synthesis and Biological Evaluation of Naphthyldesferrithiocin Iron Chelators. J. Med. Chem. 1996, 39, 1575-1581.
48. Bergeron, R. J.; Wiegand, J.; Weimar, W. R.; McManis, J. S.; Smith, R. E.; Abboud, K. A. Iron Chelation Promoted by Desazadesferrithiocin Analogues: An Enantioselective Barrier. Chirality 2003, 15, 593-599.
49. Bergeron, R. J.; Wiegand, J.; Ratliff-Thompson, K.; Weimar, W. R. The Origin of the Differences in (R)- and (S)-Desmethyldesferrithiocin: Iron-Clearing Properties. Ann. N. Y. Acad. Sci. 1998, 850, 202-216.
50. Gomori, G. Preparation of Buffers for Use in Enzyme Studies. Methods Enzymol. 1955, 1, 138-146.
51. Römer, A.; Sammet, M. Synthesis of Substituted Phenazines from Benzofurazanoxid and Hydroquinones. Z. Naturforsch., B: Chem. Sci. 1983, 38B, 866-872.
52. Bergeron, R. J.; Huang, G.; Weimar, W. R.; Smith, R. E.; Wiegand, J.; McManis, J. S. Desferrithiocin Analogue-Based Hexacoordinate Iron(III) Chelators. J. Med. Chem. 2003, 46, 16-24.